Healthcare Industry News: Millennium
News Release - November 11, 2006
Bausch & Lomb Showcases New Technologies at American Academy of Ophthalmology Annual MeetingLAS VEGAS--(HSMN NewsFeed)--At the 2006 Annual Meeting of the American Academy of Ophthalmology in Las Vegas, Nevada this week, Bausch & Lomb (NYSE: BOL ) is showcasing several technological innovations in its lines of products for cataract, vitreoretinal and refractive surgery. They include:
Stellaris(TM) Vision Enhancement System
- allows cataract surgeons to perform either standard coaxial or sub-2mm micro incision coaxial and bimanual phacoemulsification surgery; customizable for either vacuum or flow-based fluidics; ergonomically designed for optimal efficiency and ease of use. The Stellaris system will be rolled out following FDA approval which is expected in the first quarter of 2007.
Akreos(TM) AO Micro Incision Intraocular Lens
- an advanced acrylic IOL designed to be aberration-free for improved quality of vision even in low light conditions; can be inserted via a 1.8 mm wound assisted incision; incorporates an innovative four-point haptic design for exceptional centration and stability. The Akreos AO Micro Incision lens is now available in major markets outside of the United States. The Akreos Adapt AO aspheric lens, which incorporates a similar aberration-free optical design delivered through a 2.8 mm incision, is pending FDA approval and is expected to be introduced in the United States in the first quarter of 2007.
SofPort® Advanced Optics Aspheric IOL with Violet Shield(TM) Technology
- a unique IOL designed to block harmful ultraviolet and violet light to protect the retina from phototoxicity without compromising night vision or color perception, a potential side effect of current blue-blocking lens technologies. Approved for sale in the United States earlier this year, the SofPort AO Violet Shield lens will be launched worldwide in December.
Millennium(TM) Vitrectomy System with MID Labs Adaptable Vitrectomy Enhancer
Through a new strategic partnership with Medical Instrument Development Laboratories Inc. (MID Labs), Bausch & Lomb will offer the AVE with its Millennium system, providing retinal surgeons with 20 and 25 gauge vitrectomy cutters that deliver cut rates of up to 2500 cpm. The high speed lessens vitreous tractional forces, thus reducing the potential for retinal tears, and also diminishes turbulence for better control of mobile tissue. The AVE is expected to be available with the Millennium microsurgical system in the United States in early 2007.
Zyoptix® Advanced Personalized Technologies
- enhances wavefront-guided vision correction with three new diagnostic and support innovations: the Zyoptix Diagnostic Workstation II that eliminates the need to pharmaceutically dilate pupils, resulting in significantly shorter diagnostic work-up time and allowing same-day procedures; the Zyoptix Advanced Nomogram which for the first time compensates for the interaction between aberrations to optimize results; the TruLink Customer Support Network which optimizes system functionality through remote monitoring, proactive service maintenance and the option to back-up data. These new features are now available on a global basis as upgrades to the Zyoptix 217z (100 Hz) excimer laser.
Zyoptix® XP Epi Separator
- new epithelial separation technology for refractive surgery on the Zyoptix XP microkeratome platform, which now supports both LASIK and Epi-LASIK surgeries; allows surgeons to easily and efficiently switch microkeratome heads to make precise and predictable epithelial flaps in 12 seconds, a procedure that may be more appropriate for certain patients such as those with thin corneas, higher refractive errors or dry eyes. The Epi Separator recently received FDA clearance for marketing in the United States and will be available worldwide in the first quarter of 2007.
Ocuvite® Adult and Ocuvite Adult 50+ Supplements
- new vitamin and mineral formulations containing lutein and omega-3 fatty acids to promote general eye health and help supplement the unique nutritional demands of "baby boomers". Both formulations are now in full distribution on retail shelves throughout the United States.
This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of Bausch & Lomb. Such statements involve a number of risks and uncertainties including those concerning economic conditions, currency exchange rates, product development and introduction, the financial well-being of key customers, the successful execution of marketing strategies, the continued successful implementation of its efforts in managing and reducing costs and expenses, as well as the risk factors listed from time to time in the Company's SEC filings, including but not limited to filings on Form 8-K and on Form 12b-25, each dated August 8, 2006.
Bausch & Lomb is the eye health company, dedicated to perfecting vision and enhancing life for consumers around the world. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world. Founded in 1853, the Company is headquartered in Rochester, New York. Bausch & Lomb's 2004 revenues were $2.2 billion; it employs approximately 13,700 people worldwide and its products are available in more than 100 countries. More information about the Company is on the Bausch & Lomb Web site at www.bausch.com. Copyright Bausch & Lomb Incorporated.
Source: Bausch & Lomb
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.